Overview

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants

Status:
NOT_YET_RECRUITING
Trial end date:
2026-11-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VX-581.
Phase:
PHASE1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated